Please ensure Javascript is enabled for purposes of website accessibility
Incyte Stock Quote


Price as of January 27, 2023, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Incyte Returns vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
INCY +19.71% -10.27% -2.14% +4,471%
S&P -5.92% +41.69% +7.21% +790%

Incyte Company Info

Incyte isn't the only drugmaker with a JAK inhibitor, but Jakafi's differentiation as a JAK1 and JAK2 inhibitor has helped the company stay on top of the treatment paradigm for myelofibrosis.

News & Analysis

The Fool has written over 200 articles on Incyte.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 01/30/2023.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.